Cyclarity’s UDP-003 to enter clinic for acute coronary syndrome

Jan. 8, 2025

No Comments

Cyclarity Therapeutics Inc. has obtained regulatory approval to begin a first-in-human trial of UDP-003.

BioWorld Science Regulatory Cardiovascular Australia

Today's news in brief

BioWorld

BioWorld briefs for Jan. 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 9, 2025

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

BioWorld

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...

GLP-1 receptor agonists continue their global victory tour

BioWorld

2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

Upgrade your daily dose of biopharma and medtech news

Cyclarity’s UDP-003 to enter clinic for acute coronary syndrome